1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc.

JSPRW
Jasper Therapeutics, Inc.US flagNASDAQ Capital Market
0.01
USD
- -
- -
208,033.00Market Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
1
1
1
1
1
Net Income, GAAP
-32
-31
-38
-64
-71
-76
-56
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
Working Capital
17
80
35
77
61
21
11
LT Debt
2
2
3
2
1
- -
- -
Total Equity
-35
70
36
78
62
4
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
55
35
20
Cash, Cash Equivalents & STI
51
29
14
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
21
13
9
Payables & Accruals
17
10
6
ST Debt
2
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-68.56%
-93.27%
Free Cash Flow
- -
36.37%
22.19%
Net Income, GAAP
- -
21.54%
6.36%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Jeetinder Singh Mahal
Full Time Employees
64
Sector
Healthcare
Industry
Biotechnology
Address
2200 Bridge Pkwy Redwood City DE United States of America 94065
IPO Date
Jan 10, 2020
CIK
0001788028
Website
jaspertherapeutics.com
Similar Companies
Biohaven Ltd. (BHVN)
Biocon Limited (BIOCON.BO)
Medigene AG (MDGEF)
UCB S.A. (UCBJF)
Argos Therapeutics, Inc. (ARGS)
Evommune, Inc. (EVMN)
Business
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the KIT (CD117) receptor on mast cells and hematopoietic stem cells to treat chronic mast cell-driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma, as well as enabling safer conditioning for stem cell transplantation in hematologic malignancies such as sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. The company, founded in 2018 and headquartered at 2200 Bridge Parkway, Suite 102, Redwood City, California, United States, conducts clinical trials including the ongoing Phase 1b/2a BEACON study in CSU showing promising efficacy with deep and durable responses in multiple dosing cohorts, the SPOTLIGHT study in CIndU, the ETESIAN study in asthma, and open-label extensions, while also advancing briquilimab in stem cell transplant conditioning regimens demonstrated in prior studies to support engraftment without typical toxicities. Recent developments include promising July 2025 BEACON data updates despite isolated drug lot investigations concluded not related to manufacturing with final key opinion leader-reviewed results expected in Q4 2025, continued patient enrollment toward Phase 2b CSU dose selection and study start mid-2026 with additional data in early Q1 2026, a $30 million underwritten public offering of common stock and warrants completed in Q3 2025 extending cash runway through Q1 2026 alongside $50.9 million cash on hand as of September 30, 2025, and a prior $45 million private placement in October 2024.